Amarin Corp. plc, with research headquarters in Groton, has been cited as having one of the five most disappointing new drugs of the past half-decade.

The publication EvaluatePharma culled through drugs that were expected to be blockbusters but have so far proven to be less than stellar performers. And Amarin's cholesterol remedy Vascepa ended up as the fourth most disappointing drug, having seen predictions of a potential $2 billion annual market dwindle down to $505 million.

Expectations of a blockbuster evaporated when Amarin couldn't find a marketing partner. Early sales numbers are low, but the jury is still out.